GlassScriptPhysician profile
Celeste Baker Dicarlo
NPI 1336660265
$7,725.82
in general payments reported to CMS, 2019-2025
25 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $749 · 2021: $534 · 2022: $847 · 2023: $2,162 · 2024: $801 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Travel and Lodging: $1,040 · Entertainment: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.21 |
| Travel and Lodging | $1,040.31 |
| Entertainment | $156.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,577.10 | 2019-2025 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Allergan, INC. | $681.79 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $680.83 | 2019-2025 | Acuvue |
| Optos, INC. | $434.82 | 2020-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $432.85 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $382.18 | 2019-2021 | |
| Glaukos Corporation | $322.16 | 2024-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Tarsus Pharmaceuticals, INC. | $296.32 | 2024-2025 | Xdemvy |
| Coopervision INC. | $280.44 | 2019-2023 | Myday Contact Lens |
| Harrow Eye, LLC | $236.27 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $215.90 | 2019-2022 | |
| Oyster Point Pharma, INC. | $179.39 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $151.71 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $139.38 | 2019-2021 | |
| Rxsight INC | $135.83 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $118.36 | 2025 | Acthar |
| Shire North American Group INC | $104.07 | 2019 | |
| Astellas Pharma US INC | $82.63 | 2023 | |
| Genentech USA, INC. | $63.68 | 2019 | |
| Abbvie INC. | $59.69 | 2022 | |
| Kala Pharmaceuticals, INC. | $47.41 | 2021-2022 | |
| Dompe US, INC. | $33.72 | 2024 | Oxervate |
| Eyevance Pharmaceuticals LLC | $32.25 | 2020 | |
| Sight Sciences, INC. | $18.86 | 2022 | |
| Beaver-Visitec International, INC. | $18.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Dicarlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.